STAT

Limited data may be skewing assumptions about severity of coronavirus outbreak, experts say

The approach to tracking the coronavirus in China is likely resulting in both an underestimate in the total number of cases and flawed assumptions about fatality rates, experts say.
Medical staff arrive with a patient at the Wuhan Red Cross Hospital in China.

Health officials in China, racing to try to contain a fast-growing coronavirus outbreak, are principally recording severe cases of disease, using a case definition that cannot capture patients with mild illness, according to experts familiar with the surveillance efforts.

The approach, the experts told STAT, is likely resulting in both an underestimate in the total number of cases and flawed assumptions about fatality rates calculated by those who ignore the repeated caution that it’s too soon to do that math.

The experts were quick to note that the Chinese are not willfully underreporting cases. Rather, the approach is a testament to how challenging data collection can be during the early days of an

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks